- Previous Close
0.6420 - Open
0.6420 - Bid 0.6400 x --
- Ask 0.6560 x --
- Day's Range
0.6320 - 0.6640 - 52 Week Range
0.5400 - 13.2000 - Volume
294,680 - Avg. Volume
1,581,796 - Market Cap (intraday)
52.252M - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-10.3900 - Earnings Date Apr 23, 2025 - Apr 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. The company was incorporated in 2010 and is based in Oslo, Norway.
www.circio.comRecent News: CRNA.OL
View MorePerformance Overview: CRNA.OL
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRNA.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRNA.OL
View MoreValuation Measures
Market Cap
52.25M
Enterprise Value
84.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
56.17
Price/Book (mrq)
--
Enterprise Value/Revenue
686.29
Enterprise Value/EBITDA
6.87
Financial Highlights
Profitability and Income Statement
Profit Margin
7,730.08%
Return on Assets (ttm)
-110.74%
Return on Equity (ttm)
--
Revenue (ttm)
123k
Net Income Avi to Common (ttm)
9.5M
Diluted EPS (ttm)
-10.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
2.84M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-29.2M